Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $8.55 USD
Change Today 0.00 / 0.00%
Volume 0.0
BIOA On Other Exchanges
New York
EN Paris
As of 8:04 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

bioamber inc (BIOA) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/10/15 - $11.30
52 Week Low
08/5/15 - $4.64
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOAMBER INC (BIOA)

bioamber inc (BIOA) Related Bloomberg News

View More Bloomberg News

bioamber inc (BIOA) Related Businessweek News

No Related Businessweek News Found

bioamber inc (BIOA) Details

BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various chemical market customers in the United States. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into chemicals that are replacements for petroleum-derived chemicals. The company’s bio-succinic acid is used in various applications, including plasticizers, polyurethanes, personal care products, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, and food additives, as well as anti-freeze solutions, coolants solvents, water treatment chemicals, laundry tablets and bath salts, artificial leather products, and foams made with recycled polyethylene terephthalate. Its product pipeline also includes bio-succinic acid derivatives, such as 1, 4 butanediol, gamma-butyrolactone, and succinic acid based polyesters; and C6 building block chemicals comprising adipic acid, caprolactam, and hexamethylenediamine. The company sells its products directly to its customers and commercial partners, as well as indirectly through distributor in the Asia-Pacific region. It has strategic relationships with various companies, including PTTMCC Biochem Company Limited, Vinmar International Ltd., and Mitsubishi Chemical Corporation. The company was formerly known as DNP Green Technology, Inc. and changed its name to BioAmber Inc. in September 2010. BioAmber Inc. is headquartered in Montreal, Canada.

74 Employees
Last Reported Date: 03/16/15

bioamber inc (BIOA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $480.1K
Chief Operations Officer
Total Annual Compensation: $270.8K
Executive Vice President
Total Annual Compensation: $319.3K
Chief Commercial Officer
Total Annual Compensation: $298.0K
Chief Technology Officer
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2014.

bioamber inc (BIOA) Key Developments

BioAmber Inc. Announces Opening of Succinic Acid Plant in Sarnia

BioAmber Inc. announced the opening of its BioAmber Sarnia plant that was jointly built with Mitsui & Co. Ltd. BioAmber Sarnia makes renewable chemicals from sugar instead of petroleum. The new plant uses innovative biotechnology and will produce biobased succinic acid from glucose sourced from southern Ontario agricultural suppliers. The BioAmber Sarnia plant is the world's succinic acid production facility and will be globally competitive while making chemicals more sustainably.

BioAmber Inc. Enters into Second Amendment to Loan and Security Agreement with Fund Managed by Tennenbaum Capital Partners, LLC

On July 29, 2015, BioAmber Inc. entered into a Second Amendment to Loan and Security Agreement with a fund managed by Tennenbaum Capital Partners, LLC and the collateral agent under the Company's loan facility. Pursuant to the Amendment, the Company's permitted investments into BioAmber Sarnia Inc. increased from $10.0 million to $25.0 million after July 29, 2015. The unrestricted cash balance for the period from the Effective Date to December 31, 2015 that the Company is required to maintain increased from $12.5 million to $15.0 million provided however, that if the Company's revenues exceeds a minimum threshold during a given month, then the unrestricted cash for the following month shall be at $12.5 million. After December 31, 2015, the Company must maintain the lesser of $12.5 million (or $15.0 million if a certain quarterly revenue requirement is not met), and the amount of the outstanding principal on the loan or BioAmber Sarnia's trailing 6 month free cash flow must be at least 85% of certain projections agreed to with the Lender. The company is obligated to pay an amendment fee of $500,000, payable 50% on the Effective Date and 50% on the earlier of Company's sale of their respective equity interests after the Effective Date, and March 31, 2016.

BioAmber Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter Ended June 30, 2015; Reports Impairment Losses for the Second Quarter Ended June 30, 2015

BioAmber Inc. announced unaudited consolidated earnings results for the second quarter ended June 30, 2015. For the period, revenue was $342,000 against $415,000 a year ago. Operating loss was $10,894,000 against $10,378,000 a year ago. Net loss was $14,826,000 against $14,145,000 a year ago. Net loss attributable to the company’s shareholders was $14,026,000 against $13,992,000 a year ago. Net loss per share attributable to the company’s basic shareholders was $0.58 against $0.75 a year ago. Net cash used in operating activities was $15,571,000 against $7,951,000 a year ago. Acquisition of property and equipment was $52,433,000 against $32,728, 000 a year ago. Adjusted net loss attributable to the company’s shareholders was $9,529,000 against $7,465,000 a year ago. Adjusted net loss per share attributable the company’s basic shareholders was $0.39 against $0.40 a year ago. For the quarter, impairment loss was $1,141,000.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOA:US $8.55 USD 0.00

BIOA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIOA.
View Industry Companies

Industry Analysis


Industry Average

Valuation BIOA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 132.6x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 52.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOAMBER INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at